Sigrun Einarsdottir is originally Icelandic but has lived in Sweden for many years. She has completed fellowship in Internal Medicine in both Sweden and in a physician training program in Sydney, Australia. She completed fellowship in Hematology 2022 at Sahlgrenska University hospital in Gothenburg, Sweden and defended her PhD the same year entitled “Vaccine responses in patients with hematological malignancies with focus on patients after stem cell transplantation”. She is active in the Swedish Society of Hematology and served as a president of the Educational Committee 2022-2023. Main research interests are infections, immune reconstitution and vaccine responses in severely immunocompromised patients. At MSKCC the focus is infections and vaccine responses post CAR T-cell therapy.
Dr. Einarsdottir has received postdoc grants from The Swedish Foundation for International Cooperation in Research and Higher Education (STINT), The Swedish Society of Medicine (SLS), Gothenburg Medical Society (GLS), The Iris-grant and the Swedish state under the agreement between the Swedish government and the county councils (ALF).
Selected publications:
Einarsdottir S, Martner A, Waldenstrom J, Ringlander J, Arabpour M, Törnell A, Nilsson M, Lisak M, Veje M, Friman V, Bergstrom T, Ljungman P, Brune M, Hellstrand K, Lagging M. Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity. Blood Advances, 2022.
Einarsdottir S, Al-Dury S, Fridriksson A, Dahlsten-Andius A, Wang H, Sharba S, Mountagui A, Waern J, Ringlander J, Martner A, Hellstrand K, Waldenström J, Lagging M. Immunogenicity of Cominarty XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation. Scientific Reports, 2024.
Einarsdottir S, Sverrisdottir I, Villegas-Scivetti M, Day C, Turesson I, Juliusson G, Hansson M, Larfors G, Blimark C. Respiratory syncytial virus and other vaccine-preventable infections in Multiple Myeloma. A population-based study on 8672 myeloma patients diagnosed 2008-2021. Haematologica, 2024.
Einarsdottir S, Waldenstrom J, Törnell A, Ringlander J, Malmström J, Stenback J, Hellstrand K, Martner A, Lagging M. Impaired T-cell response to mRNA vaccination heralds risk of COVID-19 in long-term allogeneic hematopoietic stem cell transplant survivors. Haematologica, 2024.
Einarsdottir S, Sverrisdottir I, Vaht K, Bergstrom T, Andersson P-O, Brune M, Wenneras C, Ljungman P. Long-term immunity to diphtheria and tetanus after vaccination of allogeneic stem cell transplant recipients. Transplantion and Cellular Therapy, 2023.
Einarsdottir S, Martner A, Nicklasson M, Wiktorin G, Arababpour M, Törnell A, Vaht K, Waldenstrom J, Ringlander J, Bergstrom T, Brune M, Hellstrand K, Ljungman P, Lagging M. Reduced immunogenicity of a third COVID-19 vaccination among recipients of haematopoietic stem cell transplantation. Haematologica 2022.
Einarsdottir S, Nicklasson M, Veje M, Studahl M, Friman V, Lisak M, Roth A, Bergstrom T, Ljungman P, Brune M. Vaccination against Tick-borne encephalitis after autologous and allogeneic stem cell transplantation. Vaccine 2021.